A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome

A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome

Submitted by admin on January 4, 2024 - 10:10am
Source: 
BioPharma Dive
News Tags: 
Moonwalk Biosciences
CRISPR
gene editing
funding
Feng Zhang
Headline: 
A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome
snippet: 

Armed with $57 million in funding, Moonwalk Biosciences aims to use CRISPR tools to edit what CEO Alex Aravanis describes as the “software” of the human body.

Do Not Allow Advertisers to Use My Personal information